| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
(S)-3,5-DHPG displaces the putative group I mGlu binding site, the high-affinity squilinic acid site, specifically [1].
|
|---|---|
| ln Vivo |
(S)-3,5-DHPG (icv; 0.01, 0.1, and 1.0 nmol/5 μL) shows anti-anxiety effect and enhances consolidation and recovery in male Wistar hypoxic rats weighing 160–180 g[2].
|
| References |
|
| Additional Infomation |
(S)-3,5-dihydroxyphenylglycine is a glycine derivative that is L-alpha-phenylglycine substituted at positions 3 and 5 on the phenyl ring by hydroxy groups. It is a member of resorcinols and a non-proteinogenic L-alpha-amino acid. It is functionally related to a L-alpha-phenylglycine. It is a tautomer of a (S)-3,5-dihydroxyphenylglycine zwitterion.
|
| Molecular Formula |
C8H11NO5
|
|---|---|
| Molecular Weight |
201.17
|
| Exact Mass |
183.053
|
| CAS # |
162870-29-3
|
| Related CAS # |
DHPG;146255-66-5
|
| PubChem CID |
443586
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
448.8±33.0 °C at 760 mmHg
|
| Flash Point |
225.2±25.4 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.680
|
| LogP |
-0.52
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
187
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=C(C=C(C=C1O)O)[C@@H](C(=O)O)N
|
| InChi Key |
HOOWCUZPEFNHDT-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-2-(3,5-dihydroxyphenyl)acetic acid
|
| Synonyms |
Dihydroxyphenylglycine DHPG J516.528H
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~545.97 mM)
H2O : ~25 mg/mL (~136.49 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9709 mL | 24.8546 mL | 49.7092 mL | |
| 5 mM | 0.9942 mL | 4.9709 mL | 9.9418 mL | |
| 10 mM | 0.4971 mL | 2.4855 mL | 4.9709 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04592354 | UNKNOWN STATUS | Dietary Supplement: Oxaloacetate Medical Food/Dietary Supplement | Treatment of Fatigue After Resolution of COVID-19 Infection | Terra Biological LLC | 2020-10-15 | Not Applicable |
| NCT06317688 | ENROLLING BY INVITATION | Dietary Supplement: Extra-Virgin Coconut Oil | Breast Feeding Lactation Mastitis Staphylococcus Aureus Infection |
Texas Woman's University | 2023-11-06 | Phase 1 |
| NCT05866848 | COMPLETED | Other: Placebo Other: Anhydrous caffeine (45mg) Other: Anhydrous caffeine (120mg) |
Cardiovascular System | Escola Superior de Tecnologia da Saúde de Coimbra | 2021-05-01 | Not Applicable |
| NCT04450160 | UNKNOWN STATUS | Drug: Anhydrous Enol-Oxaloacetate (AEO)
Other: Standard of Care |
Glioblastoma Multiforme | MetVital, Inc. | 2020-12 | Phase 2 |
| NCT06239480 | RECRUITING | Drug: QTORIN 3.9% Rapamycin Anhydrous Gel | Microcystic Lymphatic Malformation | Palvella Therapeutics, Inc. | 2024-07 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
